Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
Want to see IN:MANGALAM full AI Analyst Report?
Top Page
Mangalam Drugs & Organics Ltd.
(MANGALAM)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹28.00
▼(-7.89% Downside)
Action:ReiteratedDate:02/06/26
The score is held back primarily by weak technicals (below key long-term averages with soft momentum) and a negative P/E that limits valuation support. Financial performance is mixed: profitability and revenue recently deteriorated, but leverage appears manageable and operating cash flow has improved, preventing a lower score.
Positive Factors
Specialty chemicals & API B2B model
Mangalam's core business is manufacturing specialty chemicals and APIs for B2B customers. This model benefits from recurring procurement, higher switching costs related to quality/compliance, and structural demand from pharma and chemical supply chains, supporting stable midterm revenue visibility.
Negative Factors
Declining revenue and contracting margins
Recent declines in revenue and net income, and contracting EBIT/EBITDA margins, weaken scale economics and reduce reinvestment capacity. If structural or product-mix issues persist, profitability pressure can erode competitive position, constrain R&D/capex and increase sensitivity to input cost swings.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty chemicals & API B2B model
Mangalam's core business is manufacturing specialty chemicals and APIs for B2B customers. This model benefits from recurring procurement, higher switching costs related to quality/compliance, and structural demand from pharma and chemical supply chains, supporting stable midterm revenue visibility.
Read all positive factors
Mangalam Drugs & Organics Ltd. (MANGALAM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹440.03M
Dividend YieldN/A
Average Volume (3M)5.11K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-31.38%
EPS Growth-403.40%
CountryIN
Employees432
SectorBasic Materials
Sector Strength58
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.84
Price to Sales (P/S)0.39
P/FCF Ratio5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mangalam Drugs & Organics Ltd. Business Overview & Revenue Model
Company Description
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for ...
How the Company Makes Money
Mangalam Drugs & Organics Ltd. primarily makes money by manufacturing and selling its chemical and pharmaceutical intermediate products to business customers (B2B). Revenue is generated from (1) domestic sales to Indian customers and (2) export sa...
Mangalam Drugs & Organics Ltd. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
65
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.68B | 3.18B | 3.67B | 3.70B | 4.47B | 3.80B |
| Gross Profit | 1.03B | 1.50B | 188.12M | 287.77M | 546.89M | 976.69M |
| EBITDA | 112.23M | 363.25M | 174.95M | 259.54M | 451.84M | 550.15M |
| Net Income | -197.98M | 67.21M | -90.72M | 12.70M | 196.57M | 279.71M |
Balance Sheet | ||||||
| Total Assets | 3.17B | 3.66B | 3.34B | 3.60B | 3.28B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 96.75M | 25.89M | 11.87M | 26.88M | 19.55M | 5.92M |
| Total Debt | 949.21M | 962.30M | 1.07B | 885.47M | 879.04M | 697.06M |
| Total Liabilities | 1.89B | 2.17B | 1.98B | 2.08B | 1.78B | 1.33B |
| Stockholders Equity | 1.28B | 1.49B | 1.36B | 1.52B | 1.51B | 1.31B |
Cash Flow | ||||||
| Free Cash Flow | 19.14M | 223.93M | -79.20M | 116.09M | -19.60M | -38.86M |
| Operating Cash Flow | 77.10M | 425.94M | 39.13M | 395.23M | 257.09M | 275.50M |
| Investing Cash Flow | -57.59M | -194.72M | -118.27M | -221.72M | -273.26M | -312.85M |
| Financing Cash Flow | -11.63M | -217.12M | 52.27M | -166.17M | 29.79M | 26.98M |
Mangalam Drugs & Organics Ltd. Technical Analysis
Negative
30.40
Price Trends
31.40
Negative
32.48
Negative
54.57
Negative
Market Momentum
-0.41
Negative
45.90
Neutral
40.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANGALAM, the sentiment is Negative. The current price of 30.4 is above the 20-day moving average (MA) of 29.86, below the 50-day MA of 31.40, and below the 200-day MA of 54.57, indicating a bearish trend. The MACD of -0.41 indicates Negative momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 40.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANGALAM.
Mangalam Drugs & Organics Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹1.12B | 6.49 | ― | ― | 4.84% | -9.86% | |
63 Neutral | ₹860.75M | 21.33 | ― | ― | 15.04% | -11.75% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
56 Neutral | ₹537.20M | 172.45 | ― | ― | -27.51% | 356.89% | |
50 Neutral | ₹440.03M | -1.11 | ― | ― | -31.38% | -403.40% | |
47 Neutral | ₹402.31M | -4.63 | ― | ― | -48.93% | -180.45% | |
39 Underperform | ₹561.33M | -2.21 | ― | ― | -35.33% | -65.64% |
* Basic Materials Sector Average
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
28.35
-51.15
-64.34%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
33.65
-11.63
-25.68%
IN:LASA
Lasa Supergenerics Ltd.
8.02
-9.70
-54.74%
IN:PAR
Par Drugs and Chemicals Limited
91.13
-12.03
-11.66%
IN:VAISHALI
Vaishali Pharma Ltd.
8.12
-5.62
-40.90%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.87
1.97
40.20%
Mangalam Drugs & Organics Ltd. Corporate Events
Mangalam Drugs & Organics Closes Trading Window Ahead of FY26 Results
Mar 24, 2026
Mangalam Drugs Organics Ltd. has announced the closure of its trading window for designated persons and their immediate relatives from April 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s int...
Mangalam Drugs & Organics Reshuffles Board, Appoints New CFO
Feb 6, 2026
Mangalam Drugs Organics Limited’s board met on 6 February 2026 and approved several key changes in its leadership structure and governance. The board accepted the resignation of independent director Rukmesh P. Dhandhania with effect from 16...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.